Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 5 de 5
Filter
Add more filters










Database
Language
Publication year range
2.
Sensors (Basel) ; 23(12)2023 Jun 20.
Article in English | MEDLINE | ID: mdl-37420919

ABSTRACT

The measurement of physiologic pressure helps diagnose and prevent associated health complications. From typical conventional methods to more complicated modalities, such as the estimation of intracranial pressures, numerous invasive and noninvasive tools that provide us with insight into daily physiology and aid in understanding pathology are within our grasp. Currently, our standards for estimating vital pressures, including continuous BP measurements, pulmonary capillary wedge pressures, and hepatic portal gradients, involve the use of invasive modalities. As an emerging field in medical technology, artificial intelligence (AI) has been incorporated into analyzing and predicting patterns of physiologic pressures. AI has been used to construct models that have clinical applicability both in hospital settings and at-home settings for ease of use for patients. Studies applying AI to each of these compartmental pressures were searched and shortlisted for thorough assessment and review. There are several AI-based innovations in noninvasive blood pressure estimation based on imaging, auscultation, oscillometry and wearable technology employing biosignals. The purpose of this review is to provide an in-depth assessment of the involved physiologies, prevailing methodologies and emerging technologies incorporating AI in clinical practice for each type of compartmental pressure measurement. We also bring to the forefront AI-based noninvasive estimation techniques for physiologic pressure based on microwave systems that have promising potential for clinical practice.


Subject(s)
Artificial Intelligence , Blood Pressure Determination , Humans , Blood Pressure , Blood Pressure Determination/methods , Oscillometry
3.
Drug Metab Dispos ; 51(1): 1-7, 2023 01.
Article in English | MEDLINE | ID: mdl-36153008

ABSTRACT

Cytochrome P450s (CYPs) display significant inter-individual variation in expression, much of which remains unexplained by known CYP single-nucleotide polymorphisms (SNPs). Testis-specific Y-encoded-like proteins (TSPYLs) are transcriptional regulators for several drug-metabolizing CYPs including CYP3A4 However, transcription factors (TFs) that might influence CYP expression through an effect on TSPYL expression are unknown. Therefore, we studied regulators of TSPYL expression in hepatic cell lines and their possible SNP-dependent variation. Specifically, we identified candidate TFs that might influence TSPYL expression using the ENCODE ChIPseq database. Subsequently, the expression of TSPYL1/2/4 as well as that of selected CYP targets for TSPYL regulation were assayed in hepatic cell lines before and after knockdown of TFs that might influence CYP expression through TSPYL-dependent mechanisms. Those results were confirmed by studies of TF binding to TSPYL1/2/4 gene promoter regions. In hepatic cell lines, knockdown of the REST and ZBTB7A TFs resulted in decreased TSPYL1 and TSPYL4 expression and increased CYP3A4 expression, changes reversed by TSPYL1/4 overexpression. Potential binding sites for REST and ZBTB7A on the promoters of TSPYL1 and TSPYL4 were confirmed by chromatin immunoprecipitation. Finally, common SNP variants in upstream binding sites on the TSPYL1/4 promoters were identified and luciferase reporter constructs confirmed SNP-dependent modulation of TSPYL1/4 gene transcription. In summary, we identified REST and ZBTB7A as regulators of the expression of TSPYL genes which themselves can contribute to regulation of CYP expression and-potentially-of drug metabolism. SNP-dependent modulation of TSPYL transcription may contribute to individual variation in both CYP expression and-downstream-drug response phenotypes. SIGNIFICANCE STATEMENT: Testis-specific Y-encoded-like proteins (TSPYLs) are transcriptional regulators of cytochrome P450 (CYP) gene expression. Here, we report that variation in TSPYL expression as a result of the effects of genetically regulated TSPYL transcription factors is an additional factor that could result in downstream variation in CYP expression and potentially, as a result, variation in drug biotransformation.


Subject(s)
DNA-Binding Proteins , Transcription Factors , Male , Animals , Transcription Factors/genetics , DNA-Binding Proteins/genetics , Cytochrome P-450 CYP3A/genetics , Testis , Cell Line, Tumor , Cytochrome P-450 Enzyme System/genetics
4.
Oncogene ; 41(35): 4119-4129, 2022 08.
Article in English | MEDLINE | ID: mdl-35864174

ABSTRACT

The HER2 receptor modulates downstream signaling by forming homodimers and heterodimers with other members of the HER family. For patients with HER2-positive breast cancer, Trastuzumab, an anti-HER2 monoclonal antibody as first-line therapy has shown significant survival benefits. However, the development of acquired resistance to Trastuzumab continues to be a significant obstacle. TNF receptor-associated factor 4 (TRAF4) upregulation was discovered to be associated with a worse clinical outcome. Here we identified TRAF4 overexpression as one of the putative mechanisms for HER2-positive breast cancer cells to maintain HER2 signaling during Trastuzumab treatment, while TRAF4 knockdown reduced HER2 stability and improved Trastuzumab sensitivity. Mechanistically, TRAF4 regulates HER2 level through its impact on SMAD specific E3 ubiquitin protein ligase protein 2 (SMURF2). The development of a membrane-associated protein complex containing HER2, TRAF4, and SMURF2 has been observed. SMURF2 bound to the HER2 cytoplasmic domain, and directly ubiquitinated it leading to HER2 degradation, whereas TRAF4 stabilized HER2 by degrading SMURF2 and inhibiting the binding of SMURF2 to HER2. Moreover, downregulation of TRAF4 has decreased the AKT/mTOR signaling. In conclusion, we discovered a new HER2 signaling regulation that involves the TRAF4-SMURF2 complex, a possible mechanism that might contribute to anti-HER2 resistance, making TRAF4 a viable target for treating HER2 + breast cancer.


Subject(s)
Breast Neoplasms , TNF Receptor-Associated Factor 4 , Cell Line, Tumor , Drug Resistance, Neoplasm , Female , Humans , Receptor, ErbB-2 , Signal Transduction , Trastuzumab , Ubiquitin-Protein Ligases
5.
Annu Int Conf IEEE Eng Med Biol Soc ; 2018: 5990-5993, 2018 Jul.
Article in English | MEDLINE | ID: mdl-30441701

ABSTRACT

Atrial fibrillation (AF) is the most common sustained cardiac arrhythmia affecting approximately 3 million Americans, and is a prognostic marker for stroke, heart failure and even death. Current techniques to discriminate normal sinus rhythm (NSR) and AF from single lead ECG suffer several limitations in terms of sensitivity and specificity using short time ECG data which distorts ECG and many are not suitable for real-time implementation. The purpose of this research was to test the feasibility of discriminating single lead ECG's with normal sinus rhythm (NSR) and AF using intrinsic mode function (IMF) complexity index. 15 sets of ECG's with NSR and AF were obtained from Physionet database. Custom MATLAB® software was written to compute IMF index for each of the data set and compared for statistical significance. The mean IMF index for NSR across 15 data sets was 0.37 ± 0.08, and the mean IMF index for ECG with AF was 0.21 ± 0.07 showing robust discrimination with statistical significance (p<0.01). IMF complexity robustly discriminates single lead ECG with normal sinus rhythm and AF. Further validation of this result is required on a larger dataset. The results also motivate the use of this technique for analysis of other complex cardiac arrhythmias such as ventricular tachycardia (VT) or ventricular fibrillation (VF).


Subject(s)
Atrial Fibrillation/diagnosis , Electrocardiography , Signal Processing, Computer-Assisted , Humans , Sensitivity and Specificity
SELECTION OF CITATIONS
SEARCH DETAIL
...